Chart-Typ:
Zeitraum:
| Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces PDUFA Goal Date of August 15, 2025, for FDA Decision on U.S. Marketing Approval for TNX-102 SL for Fibromyalgia | Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025 TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast... ► Artikel lesen |
| Tonix Pharmaceuticals Holding: Tonix's TNX 102-SL Could Offer New Hope of Pain Relief Without Narcotics for Fibromyalgia Sufferers | This post was written and published as a collaboration between the in-house editorial team at Benzinga and Tonix Pharmaceuticals Holding Corp. with financial support from Tonix. The two organizations... ► Artikel lesen |
| Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Expansion of Leadership Team with Two Strategic Hires | Tonix appoints two executives with decades of experience successfully launching and commercializing new CNS products Bradley Raudabaugh, MBA, joins as Vice President, Marketing, bringing over 25 years... ► Artikel lesen |
| Harrow Health Aktie: Stabile Aussichten? | Der Aktienkurs des Augenheilkunde-Spezialisten Harrow Health verzeichnete am 07. Dezember einen bemerkenswerten Anstieg von 5,08 Prozent auf 39,32 USD. Die Entwicklung steht im Kontrast zum negativen... ► Artikel lesen |
| Pre-market Movers: California BanCorp, Harrow, Inc., Quantum Computing, BTC Digital, Calidi Biotherapeutics | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.15 A.M. ET).In the Green California BanCorp. (BCAL) is up over 33% at $23.01.
Quantum... ► Artikel lesen |
| Harrow Health, Inc. Announces Third Quarter 2024 Financial Results | NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, announced results for the third quarter and nine months ended September 30, 2024.... ► Artikel lesen |
| NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Appoints Michael Abrams as Chief Financial Officer | Industry veteran with extensive experience in key areas of focus
Interim-CFO Richard Narido to focus on HOPE Therapeutics acquisition opportunities
WILMINGTON, Del., Nov. 18, 2024... ► Artikel lesen |
| NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update | On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone)... ► Artikel lesen |
| HOPE Therapeutics, Inc. and NRx Pharmaceuticals, Inc. (Nasdaq:NRXP) Announce Signing of a Letter of Intent to Acquire its First Florida Interventional Psychiatry Clinics | The clinics are located in favorable locations, are revenue generating and EBITDA positive
Clinics offer a comprehensive range of mental health services
Acquisition is expected to... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ODI PHARMA AB finden Sie auf Wallstreet Online.
